| 2025-11-18 |
详情>>
内部人交易：
Holbrook Kerr共交易4笔
|
| 2025-11-05 |
详情>>
股本变动：
变动后总股本4641.89万股
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.55美元,归母净利润-7160万美元,同比去年增长-1476.92%
|
| 2025-11-05 |
财报披露：
美东时间 2025-11-05 盘前发布财报
|
| 2025-08-05 |
详情>>
业绩披露：
2025年中报每股收益-1.52美元,归母净利润-7020万美元,同比去年增长-7900%
|
| 2025-05-06 |
详情>>
业绩披露：
2025年一季报每股收益0.14美元,归母净利润660.00万美元,同比去年增长833.33%
|
| 2025-03-14 |
股东大会：
将于2025-04-24召开股东大会
会议内容 ▼▲
- 1.To elect as directors the five nominees named in the accompanying proxy statement for a one-year term;
2.To ratify the appointment of Deloitte & Touche LLP as the Company’s independent auditors for 2025;
3.To approve on an advisory basis the compensation of the Company’s named executive officers;
4.To approve an amendment to the Company’s 2021 Long Term Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,250,000 shares;
5.To take action upon any other business that may properly come before the meeting or any adjournment of the meeting.
|
| 2025-02-26 |
详情>>
业绩披露：
2024年年报每股收益-8.53美元,归母净利润-3.92亿美元,同比去年增长-534.47%
|
| 2025-02-26 |
详情>>
业绩披露：
2022年年报每股收益1.08美元,归母净利润5050.00万美元,同比去年增长701.59%
|
| 2024-10-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.11美元,归母净利润520.00万美元,同比去年增长107.19%
|
| 2024-07-31 |
详情>>
业绩披露：
2024年中报每股收益0.02美元,归母净利润90.00万美元,同比去年增长101.31%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益-0.02美元,归母净利润-90万美元,同比去年增长-80%
|
| 2024-03-15 |
股东大会：
将于2024-04-25召开股东大会
会议内容 ▼▲
- 1.To elect as directors the five nominees named in the accompanying proxy statement for a one-year term;
2.To approve on an advisory basis the compensation of the Company’s named executive officers;
3.To ratify the appointment of Deloitte & Touche LLP as the Company’s independent auditors for 2024;
4.To take action upon any other business that may properly come before the meeting or any adjournment of the meeting.
|
| 2024-02-21 |
详情>>
业绩披露：
2023年年报每股收益-1.32美元,归母净利润-6180万美元,同比去年增长-222.38%
|
| 2023-11-01 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.55美元,归母净利润-7230万美元,同比去年增长-315.18%
|
| 2023-08-09 |
复牌提示：
2023-08-09 08:42:28 停牌，复牌日期 2023-08-09 10:55:05
|
| 2023-03-17 |
股东大会：
将于2023-04-27召开股东大会
会议内容 ▼▲
- 1.To elect as directors the six nominees named in the accompanying proxy statement for a one-year term;
2.To ratify the appointment of Deloitte & Touche LLP as the Company’s independent auditors for 2023;
3.To approve on an advisory basis the compensation of the Company’s named executive officers;
4.To approve an amendment to the Company’s 2021 Long Term Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 1,250,000 shares;
5.To take action upon any other business that may properly come before the meeting or any adjournment of the meeting.
|
| 2022-03-18 |
股东大会：
将于2022-04-28召开股东大会
会议内容 ▼▲
- 1.To elect as directors the five nominees named in the accompanying proxy statement for a one-year term;
2.To ratify the appointment of Deloitte & Touche LLP as the Company’s independent auditors for 2022;
3.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-19 |
股东大会：
将于2021-04-29召开股东大会
会议内容 ▼▲
- 1.To elect as directors the two nominees named in the accompanying proxy statement for a one-year term;
2.To ratify the selection of Deloitte & Touche LLP as our independent auditors for 2021;
3.To approve a non-binding resolution to approve the compensation of our named executive officers;
4.To approve a non-binding resolution to approve the frequency of stockholder votes on our named executive officers’ compensation;
5.To approve our 2021 Long Term Incentive Plan;
6.To take action upon any other business that may properly come before the meeting or any adjournments of the meeting.
|
| 2020-03-16 |
股东大会：
将于2020-04-30召开股东大会
会议内容 ▼▲
- 1.To elect as directors the two nominees named in the accompanying proxy statement for a three-year term;
2.To ratify the selection of Deloitte & Touche LLP as our independent auditors for 2020;
3.To approve a non-binding resolution to approve the compensation of our named executive officers;
4.To approve amendments to our Certificate of Incorporation to declassify our Board of Directors;
5.To take action upon any other business that may properly come before the meeting or any adjournments of the meeting.
|
| 2019-03-15 |
股东大会：
将于2019-04-25召开股东大会
会议内容 ▼▲
- 1.The election of the three nominees named in this proxy statement as directors for a three-year term;
2.The ratification of the selection of Deloitte & Touche LLP as our independent auditors for 2019;
3.A non-binding resolution to approve the compensation of our named executive officers;
4.The Avanos Medical, Inc. Employee Stock Purchase Plan;
5.Any other business that may properly come before the meeting or any adjournments of the meeting.
|
| 2018-03-09 |
股东大会：
将于2018-04-26召开股东大会
会议内容 ▼▲
- 1.To elect as directors the three nominees named in the accompanying proxy statement for a three-year term;
2.To ratify the selection of Deloitte & Touche LLP as our independent auditors for 2018;
3.To approve a non-binding resolution to approve the compensation of our named executive officers;
4.To take action upon any other business that may properly come before the meeting or any adjournments of the meeting.
|
| 2017-03-10 |
股东大会：
将于2017-04-27召开股东大会
会议内容 ▼▲
- 1.To elect as directors the three nominees named in the accompanying proxy statement for a three-year term;
2.To ratify the selection of Deloitte & Touche LLP as our independent auditors for 2017;
3.To approve a non-binding resolution to approve the compensation of our named executive officers;
4.To take action upon any other business that may properly come before the meeting or any adjournments of the meeting.
|
| 2016-03-11 |
股东大会：
将于2016-04-28召开股东大会
会议内容 ▼▲
- 1.To elect as directors the three nominees named in the accompanying proxy statement for a three-year term;
2.To ratify the selection of Deloitte & Touche LLP as our independent auditors for 2016;
3.To approve a non-binding resolution to approve the compensation of our named executive officers;
4.To approve the material terms of the performance goals under the Company’s Equity Participation Plan;
5.To take action upon any other business that may properly come before the meeting or any adjournments of the meeting.
|